There's a new frontier in treating autoimmune diseases. Today's treatments tamp down the friendly fire but don't fix what's ...

Millions of people worldwide live with mitochondrial diseases. These are inherited conditions that make it hard for the ...

Researchers at the University of Barcelona found that combining pemafibrate and telmisartan significantly reduces liver fat and cardiovascular risks in MASLD models. The drug duo works better together ...

With our research, we show that there are other possibilities, mainly pharmacological, to treat the embryo and prevent the transmission of these types of disease," adds Marcos Roberto Chiaratti, a ...

UNC School of Medicine researchers have led an international clinical trial of patients with generalized myasthenia gravis, finding the therapy is safe and effective across all subtypes.

Metabolic dysfunction-associated steatotic liver disease is the most common liver disease in the world, affecting about one third of the adult population. This disorder is characterized by the ...

Drug-coated stents and balloons were not associated with reduced risk of amputation or improved quality of life compared with uncoated devices in two trials in peripheral artery disease (PAD), ...

Metabolic dysfunction-associated steatotic liver disease (MASLD), formerly known as nonalcoholic fatty liver disease, is the most common chronic liver disease, affecting almost 40% of adults worldwide ...